Therapeutic Response

EGFR positive and Wild type KRAS status confers therapeutic sensitivity to Cetuximab in combination with Fluorouracil and Irinotecan in patients with Colorectal Adenocarcinoma.

Statements

Source and description
Erbitux (cetuximab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to cetuximab in combination with FOLFIRI for the first-line treatment of patients with K-Ras wild-type, EGFR-expressing metastatic colorectal cancer as determined by an FDA-approved test.
Erbitux (cetuximab) [product monograph]. HC. Health Canada approved cetuximab for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment.